Held by 3 specialist biotech funds
High Convergence# Signal Note: RA Capital initiates $66.9M position in LENZ RA Capital's new $66.9M stake in LENZ signals conviction in the company's engineered probiotic platform for inflammatory bowel disease.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates LENZ Position Perceptive's $800K entry into LENZ suggests conviction in the company's pipeline, likely driven by LENZ-611 (a potential treatment for inherited retinal diseases targeting the LCA5 locus) advancing toward clinical catalysts. Edelman's firm has historically backed clinical-stage biotech with strong mechanistic rationales, signaling confidence in LENZ's target validation and near-term data readouts. Watch for IND clearance or Phase 1/2 initiation timelines in the next 12-18 months as key validation points.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial